United Therapeutics Corporation (UTHR)

NASDAQ: UTHR · USD

$586

-4.91 (-0.8%)· Recorded snapshot

Market cap	25.1B
Revenue (ttm)	3.2B
Net income (ttm)	1.3B
EPS (ttm)	$27.9
Shares out	42.9M
P/E (trailing)	21.0x
P/E (forward)	20.6x
Volume	282,829
Beta	0.49

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 3.2B
Net income (ttm): 1.3B
EPS (ttm): $27.9
P/E (trailing): 21.0x
P/E (forward): 20.6x
Market cap: 25.1B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E20.6

P25 n/aP50 n/aP75 n/a

Trailing P/E21

P25 n/aP50 n/aP75 n/a

ROE19.3

P25 n/aP50 n/aP75 n/a

ROIC31.3

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All UTHR indicators

Market & fundamental data

Available fields

275

Groups with data

Currency

USD

Showing 275 of 275 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001082554
Company name	United Therapeutics Corporation
Country	United States
Country code	US
CUSIP number	91307C102
Earnings date	2026-11-04
Earnings time	bmo
Employees	1,400
Employees change	95
Employees growth	7.28%
Enterprise value	$21.3B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1996
Industry	Drug Manufacturers - Specialty & Generic
IPO date	1999-06-17
Is primary listing	Yes
Is SPAC	No
ISIN number	US91307C1027
Last 10-K release date	2026-02-25
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split date	2009-09-23
Last stock split type	Forward
Market cap	$25.1B
Market cap category	Large-Cap
Next earnings date	2026-11-04
Options	Yes
Price	$586.31
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	UTHR
U.S. state	Maryland
Website	https://www.unither.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	20.98x
Average P/E ratio (10Y)	12.96x
Average P/E ratio (3Y)	13.63x
Average P/E ratio (5Y)	14.38x
Earnings yield	4.77%
EV/Earnings	16.23x
EV/EBIT	15.14x
EV/EBITDA	14.22x
EV/FCF	19.46x
EV/Sales	6.74x
FCF / EV yield	5.14%
FCF yield	4.36%
Forward EV/Sales	6.56x
Forward P/E	20.62x
Forward P/S	7.73x
Graham number	307.09563
Graham upside	-47.47%
Industry forward P/E	13.86x
Industry P/E	173.47x
Lynch fair value	$635.09
Lynch upside	8.63%
P/(FCF - SBC) ratio	26.74x
P/(OCF - SBC) ratio	16.39x
P/B ratio	3.94x
P/E ratio	20.98x
P/FCF ratio	22.94x
P/OCF ratio	14.88x
P/S ratio	7.95x
PEG ratio	3.17x
Price / tangible book value	3.99x
Price/EBITDA ratio	16.76x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	44.53%
EBITDA margin	47.43%
Effective tax rate	16.66%
FCF margin	34.65%
Gross margin	86.14%
Operating margin	44.53%
Pretax margin	49.87%
Profit margin	41.56%
Profit per employee	$936,357
Profitable quarters	29
Profitable years	6
Revenue per employee	$2.3M
ROA	11.61%
ROA (5Y)	11.19%
ROCE	21.24%
ROE	19.32%
ROE (5Y)	17.35%
ROIC	31.28%
ROIC (5Y)	27.79%
SBC / revenue	4.93%
Tax / revenue	8.31%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	9.04%
EPS growth (Q)	13.42%
EPS growth (QoQ)	24.91%
EPS growth 10Y	3.05%
EPS growth 3Y	16.53%
EPS growth 5Y	22.22%
EPS growth quarters	1
EPS growth years	4
FCF growth	2.05%
FCF growth (Q)	58.76%
FCF growth (QoQ)	-43.28%
FCF growth 3Y	17.51%
FCF growth 5Y	14.31%
Gross profit growth	-0.78%
Gross profit growth (Q)	-3.83%
Gross profit growth 3Y	12.7%
Gross profit growth 5Y	13.05%
Net income growth	5.54%
Net income growth (Q)	7.59%
Net income growth (QoQ)	21.13%
Net income growth 3Y	14.58%
Net income growth 5Y	22.72%
Net income growth quarters	1
Net income growth years	4
OCF growth	22.89%
OCF growth (Q)	63.59%
OCF growth (QoQ)	-32.31%
OCF growth 10Y	13.28%
OCF growth 3Y	24.76%
OCF growth 5Y	22.33%
Operating income growth	-9.04%
Operating income growth (Q)	-14.34%
Operating income growth 3Y	8.59%
Operating income growth 5Y	19.32%
Revenue growth	2.49%
Revenue growth (Q)	-1.92%
Revenue growth (QoQ)	0.23%
Revenue growth 10Y	7.21%
Revenue growth 3Y	14.33%
Revenue growth 5Y	14.68%
Revenue growth years	6

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-592.2M
Depreciation and amortization	$91.5M
EBIT	$1.4B
EBITDA	$1.5B
EPS	$27.95
FCF per share	$25.48
Financing cash flow	$-2.2B
Free cash flow	$1.1B
Free cash flow minus SBC	$937.6M
Gross profit	$2.7B
Income taxes	$262.1M
Investing cash flow	$744.5M
Net cash flow	$210.1M
Net income	$1.3B
Operating cash flow minus SBC	$1.5B
Operating income	$1.4B
Revenue	$3.2B
Stock-based compensation	$155.4M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	18.19
Book value per share	$149.97
Debt / equity	0
Interest coverage	117.06
Long-term assets	$3.7B
Long-term liabilities	$212M
Net cash (debt)	$3.8B
Net cash / market cap	15.17%
Net cash growth	-23.42%
Net debt / EBITDA	-2.54
Net debt / equity	-0.59
Net debt / FCF	-3.48
Piotroski F-Score	4
Property, plant and equipment	$1.9B
Shareholders' equity	$6.4B
Tangible book value	$6.3B
Tangible book value per share	$147.30
Total assets	$7.2B
Total cash	$2.7B
Total debt	$0
Total liabilities	$819.8M
WACC	6.94%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.42
Current assets	$3.5B
Current liabilities	$607.8M
Current ratio	5.73
Inventory turnover	2.41
Net working capital	$213.6M
Quick ratio	4.89
Working capital	$2.9B
Working capital turnover	1.02

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	3.2%
Dividend yield	0%
Shareholder yield	3.2%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	402.1%
10Y return CAGR	17.51%
10Y total return	402.1%
150-day SMA	$542.48
15Y price change	1,236.09%
15Y return CAGR	18.87%
15Y total return	1,236.09%
1D price change	-0.83%
1M price change	22.86%
1M total return	22.86%
1W price change	5.46%
1W total return	5.46%
1Y price change	38.74%
1Y return CAGR	38.77%
1Y total return	38.74%
20-day SMA	$556.36
200-day SMA	$530.33
20Y price change	1,814.27%
20Y return CAGR	15.9%
20Y total return	1,814.27%
3M price change	10.65%
3M total return	10.65%
3Y price change	166.45%
3Y return CAGR	38.63%
3Y total return	166.45%
50-day SMA	$524.21
50-day SMA vs 200-day SMA	50under200
52-week high	$609.35
52-week high date	2026-05-06
52-week low	$409.07
52-week low date	2025-10-28
5Y price change	213.82%
5Y return CAGR	25.7%
5Y total return	213.82%
6M price change	3.03%
6M total return	3.03%
All-time high	$609.35
All-time high date	2026-05-06
All-time low	$4.28
All-time low date	2001-12-11
Average true range (ATR)	$17.66
Average volume	773.7K
Beta (1Y)	0.24
Beta (2Y)	0.5
Beta (5Y)	0.49
Change from 52-week high	-3.78%
Change from 52-week low	43.33%
Change from all-time high	-4.14%
Change from all-time low	13,564.09%
Change from open	0.05%
Day's gap	-0.88%
Dollar volume	$165.8M
High price	$588.42
Low price	$583.53
Monthly RSI	70.53
Open price	$586.01
Position in 52-week range	56.75%
Premarket change	-1.89%
Premarket close	$591.20
Premarket price	$580.00
Premarket volume	103
Previous close	$591.20
Price vs 150-day SMA	7.68%
Price vs 20-day SMA	4.99%
Price vs 200-day SMA	10.15%
Price vs 50-day SMA	11.43%
Relative volume	0.37
RSI	65.47
Sharpe ratio	0.98
Sharpe ratio (3Y)	0.92
Sharpe ratio (5Y)	0.69
Sortino ratio	2.18
Sortino ratio (3Y)	1.81
Sortino ratio (5Y)	1.33
Volume	282.8K
Weekly RSI	62.1
YTD price change	19.89%
YTD total return	19.89%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	39.2M
Float percentage	91.43%
Shares change (QoQ)	-2.97%
Shares change (YoY)	-3.2%
Shares held by insiders	1.95%
Shares held by institutions	92.71%
Shares outstanding	42.9M
Short % of float	9.17%
Short % of shares	8.39%
Short ratio	4.2 days

Deeper analysis on UTHR

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this UTHR report

Is a complete UTHR research report available?

No complete published report is available for United Therapeutics Corporation (UTHR) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

United Therapeutics Corporation (UTHR)

Price

Financial snapshot

Fair-value bridge

Latest news · UTHR

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All UTHR indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on UTHR

Frequently asked questions